TY  - JOUR
A1  - Queck, Alexander David Roger
A1  - Uschner, Frank Erhard
A1  - Ferstl, Philip
A1  - Schulz, Martin
A1  - Brol, Maximilian
A1  - Praktiknjo, Michael
A1  - Schierwagen, Robert
A1  - Klein, Sabine
A1  - Straßburg, Christian P.
A1  - Meyer, Carsten
A1  - Jansen, Christian
A1  - Berres, Marie-Luise
A1  - Trebicka, Jonel
T1  - Role of circulating angiogenin levels in portal hypertension and TIPS
T2  - PLOS ONE
N2  - Background: Pathogenesis of portal hypertension is multifactorial and includes pathologic intrahepatic angiogenesis, whereby TIPS insertion is an effective therapy of portal hypertension associated complications. While angiogenin is a potent contributor to angiogenesis in general, little is known about its impact on TIPS function over time. Methods: In a total of 118 samples from 47 patients, angiogenin concentrations were measured in portal and inferior caval vein plasma at TIPS insertion (each blood compartment n = 23) or angiographic intervention after TIPS (each blood compartment n = 36) and its relationship with patient outcome was investigated. Results: Angiogenin levels in the inferior caval vein were significantly higher compared to the portal vein (P = 0.048). Ten to 14 days after TIPS, inferior caval vein angiogenin level correlated inversely with the portal systemic pressure gradient (P<0.001), measured invasively during control angiography. Moreover, patients with TIPS revision during this angiography, showed significantly lower angiogenin level in the inferior caval vein compared to patients without TIPS dysfunction (P = 0.01). Conclusion: In cirrhosis patients with complications of severe portal hypertension, circulating levels of angiogenin are derived from the injured liver. Moreover, angiogenin levels in the inferior caval vein after TIPS may predict TIPS dysfunction.
KW  - Angiography
KW  - Blood
KW  - Cirrhosis
KW  - Portal veins
KW  - White blood cells
KW  - Angiogenesis
KW  - Blood plasma
KW  - Portal hypertension
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/64430
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-644304
SN  - 1932-6203
N1  - The authors were supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 Project ID 36842431, CRC1382 Project-ID 403224013), Cellex Foundation, and European Union’s Horizon 2020 research and innovation program’s GALAXY study (No. 668031), LIVERHOPE (No. 731875) and MICROB-PREDICT (No. 825694). The manuscript reflects only the authors’ views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.
VL  - 16
IS  - 8, art. e0256473
SP  - 1
EP  - 13
PB  - PLOS
CY  - San Francisco, California, US
ER  -